Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC)
Authors
Ramalingam, S. S.Ahn, M. J.
Akamatsu, H.
Blackhall, Fiona H
Borghaei, H.
Hummel, H. D.
Johnson, M. L.
Reck, M.
Zhang, Y.
Jandial, D.
Cheng, S.
Paz-Ares, L. G.
Affiliation
Winship Cancer Institute of Emory University, Atlanta, GAIssue Date
2022
Metadata
Show full item recordCitation
Ramalingam SS, Ahn MJ, Akamatsu H, Blackhall FH, Borghaei H, Hummel HD, et al. Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680305117.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.TPS8603Type
Meetings and Proceedingsae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.TPS8603